Found 46 results
Author [ Keyword(Asc)] Title Type Year
Filters: Author is Karplus, P Andrew  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Transfection
Myzak MC, P Karplus A, Chung F-L, Dashwood RH.  2004.  A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase.. Cancer Res. 64(16):5767-74.
Transcription Factors
Myzak MC, P Karplus A, Chung F-L, Dashwood RH.  2004.  A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase.. Cancer Res. 64(16):5767-74.
Transcription Factor 7-Like 2 Protein
Myzak MC, P Karplus A, Chung F-L, Dashwood RH.  2004.  A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase.. Cancer Res. 64(16):5767-74.
Trans-Activators
Myzak MC, P Karplus A, Chung F-L, Dashwood RH.  2004.  A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase.. Cancer Res. 64(16):5767-74.
Thiocyanates
Myzak MC, P Karplus A, Chung F-L, Dashwood RH.  2004.  A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase.. Cancer Res. 64(16):5767-74.
TCF Transcription Factors
Myzak MC, P Karplus A, Chung F-L, Dashwood RH.  2004.  A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase.. Cancer Res. 64(16):5767-74.
Sulfoxides
Krueger SK, Henderson MC, Siddens LK, VanDyke JE, Benninghoff AD, P Karplus A, Furnes B, Schlenk D, Williams DE.  2009.  Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K.. Drug Metab Dispos. 37(8):1785-91.
Structure-Activity Relationship
Krueger SK, Henderson MC, Siddens LK, VanDyke JE, Benninghoff AD, P Karplus A, Furnes B, Schlenk D, Williams DE.  2009.  Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K.. Drug Metab Dispos. 37(8):1785-91.
Recombinant Proteins
Krueger SK, Henderson MC, Siddens LK, VanDyke JE, Benninghoff AD, P Karplus A, Furnes B, Schlenk D, Williams DE.  2009.  Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K.. Drug Metab Dispos. 37(8):1785-91.
Protein Denaturation
Krueger SK, Henderson MC, Siddens LK, VanDyke JE, Benninghoff AD, P Karplus A, Furnes B, Schlenk D, Williams DE.  2009.  Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K.. Drug Metab Dispos. 37(8):1785-91.
Protein Conformation
Krueger SK, Henderson MC, Siddens LK, VanDyke JE, Benninghoff AD, P Karplus A, Furnes B, Schlenk D, Williams DE.  2009.  Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K.. Drug Metab Dispos. 37(8):1785-91.
Polymorphism, Single Nucleotide
Krueger SK, Henderson MC, Siddens LK, VanDyke JE, Benninghoff AD, P Karplus A, Furnes B, Schlenk D, Williams DE.  2009.  Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K.. Drug Metab Dispos. 37(8):1785-91.
Phenotype
Krueger SK, Henderson MC, Siddens LK, VanDyke JE, Benninghoff AD, P Karplus A, Furnes B, Schlenk D, Williams DE.  2009.  Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K.. Drug Metab Dispos. 37(8):1785-91.
Oxygenases
Krueger SK, Henderson MC, Siddens LK, VanDyke JE, Benninghoff AD, P Karplus A, Furnes B, Schlenk D, Williams DE.  2009.  Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K.. Drug Metab Dispos. 37(8):1785-91.
Oxidation-Reduction
Krueger SK, Henderson MC, Siddens LK, VanDyke JE, Benninghoff AD, P Karplus A, Furnes B, Schlenk D, Williams DE.  2009.  Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K.. Drug Metab Dispos. 37(8):1785-91.
NADP
Krueger SK, Henderson MC, Siddens LK, VanDyke JE, Benninghoff AD, P Karplus A, Furnes B, Schlenk D, Williams DE.  2009.  Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K.. Drug Metab Dispos. 37(8):1785-91.
Models, Molecular
Krueger SK, Henderson MC, Siddens LK, VanDyke JE, Benninghoff AD, P Karplus A, Furnes B, Schlenk D, Williams DE.  2009.  Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K.. Drug Metab Dispos. 37(8):1785-91.
Magnesium
Krueger SK, Henderson MC, Siddens LK, VanDyke JE, Benninghoff AD, P Karplus A, Furnes B, Schlenk D, Williams DE.  2009.  Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K.. Drug Metab Dispos. 37(8):1785-91.
Kinetics
Krueger SK, Henderson MC, Siddens LK, VanDyke JE, Benninghoff AD, P Karplus A, Furnes B, Schlenk D, Williams DE.  2009.  Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K.. Drug Metab Dispos. 37(8):1785-91.
Kidney
Myzak MC, P Karplus A, Chung F-L, Dashwood RH.  2004.  A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase.. Cancer Res. 64(16):5767-74.
Isothiocyanates
Myzak MC, P Karplus A, Chung F-L, Dashwood RH.  2004.  A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase.. Cancer Res. 64(16):5767-74.
Isoenzymes
Krueger SK, Henderson MC, Siddens LK, VanDyke JE, Benninghoff AD, P Karplus A, Furnes B, Schlenk D, Williams DE.  2009.  Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K.. Drug Metab Dispos. 37(8):1785-91.
Hydroxamic Acids
Myzak MC, P Karplus A, Chung F-L, Dashwood RH.  2004.  A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase.. Cancer Res. 64(16):5767-74.
Hydrogen-Ion Concentration
Krueger SK, Henderson MC, Siddens LK, VanDyke JE, Benninghoff AD, P Karplus A, Furnes B, Schlenk D, Williams DE.  2009.  Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K.. Drug Metab Dispos. 37(8):1785-91.
Humans
Myzak MC, P Karplus A, Chung F-L, Dashwood RH.  2004.  A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase.. Cancer Res. 64(16):5767-74.

Pages